celecoxib has been researched along with Angor Pectoris in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty patients with stable angina pectoris entered a randomized, double-blind study and were assigned to receive celecoxib (200 mg 2 times daily) or placebo 7 days before percutaneous coronary intervention (PCI)." | 9.12 | Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. ( Cianfrocca, C; Granatelli, A; Mercuro, G; Pasceri, V; Pelliccia, F; Pristipino, C; Richichi, G; Roncella, A; Speciale, G, 2006) |
| "Fifty patients with stable angina pectoris entered a randomized, double-blind study and were assigned to receive celecoxib (200 mg 2 times daily) or placebo 7 days before percutaneous coronary intervention (PCI)." | 5.12 | Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. ( Cianfrocca, C; Granatelli, A; Mercuro, G; Pasceri, V; Pelliccia, F; Pristipino, C; Richichi, G; Roncella, A; Speciale, G, 2006) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, HJ | 1 |
| Oh, IY | 1 |
| Chung, JW | 1 |
| Yang, HM | 1 |
| Suh, JW | 1 |
| Park, KW | 1 |
| Kwon, TK | 1 |
| Lee, HY | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Koo, BK | 1 |
| Kang, WY | 1 |
| Kim, W | 1 |
| Rha, SW | 1 |
| Bae, JH | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Kim, HS | 1 |
| Huang, WF | 1 |
| Hsiao, FY | 1 |
| Tsai, YW | 1 |
| Wen, YW | 1 |
| Shih, YT | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Pelliccia, F | 1 |
| Pasceri, V | 1 |
| Granatelli, A | 1 |
| Pristipino, C | 1 |
| Speciale, G | 1 |
| Roncella, A | 1 |
| Cianfrocca, C | 1 |
| Mercuro, G | 1 |
| Richichi, G | 1 |
3 trials available for celecoxib and Angor Pectoris
| Article | Year |
|---|---|
Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atherosclerosis; Blood Pressure; Celecoxib; Coronar | 2012 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; Celecoxib; Combined Modality Therapy; C | 2006 |
1 other study available for celecoxib and Angor Pectoris
| Article | Year |
|---|---|
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |